Welcome to Hodoodo Chemicals

7-OH-DPAT Hydrobromide
featured

WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H527758

CAS#: 76135-30-3

Description: 7-OH-DPAT Hydrobromide is a potent and selective Dopamine D3 receptor agonist.

Chemical Structure

7-OH-DPAT Hydrobromide

CAS# 76135-30-3

Instruction

Theoretical Analysis

Hodoodo Cat#: H527758
Name: 7-OH-DPAT Hydrobromide
CAS#: 76135-30-3
Chemical Formula: C16H26BrNO
Exact Mass: 327.12
Molecular Weight: 328.294
Elemental Analysis: C, 58.54; H, 7.98; Br, 24.34; N, 4.27; O, 4.87

Price and Availability

Size	Price	Availability
5mg	USD 220	2 Weeks
10mg	USD 360	2 Weeks
25mg	USD 620	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. Hodoodo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: 7-OH-DPAT Hydrobromide

IUPAC/Chemical Name: 7-Hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide

InChi Key: ODNDMTWHRYECKX-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H25NO.BrH/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15;/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3;1H

SMILES Code: CCCN(CCC)C1CC2=C(C=CC(O)=C2)CC1.[H]Br

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 328.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Eguibar JR, Cortes Mdel C, Lara-Lozano M, Mendiola DM. Dopaminergic D2-like agonists produce yawning in the myelin mutant taiep and Sprague-Dawley rats. Pharmacol Biochem Behav. 2012 Jul;102(1):118-23. doi: 10.1016/j.pbb.2012.03.020. Epub 2012 Mar 31. PubMed PMID: 22497991.

2: Yoshizawa K, Narita M, Mori T, Miyatake M, Isotani K, Tomiyasu S, Tsukiyama Y, Suzuki T. Role of dopamine D2 and D3 receptors in mediating the U-50,488H discriminative cue: comparison with methamphetamine and cocaine. Addict Biol. 2012 Nov;17(6):949-55. doi: 10.1111/j.1369-1600.2010.00257.x. Epub 2010 Nov 4. PubMed PMID: 21054688.

3: Maina FK, Mathews TA. A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum. ACS Chem Neurosci. 2010 Mar 12;1(6):450-462. PubMed PMID: 20567609; PubMed Central PMCID: PMC2887711.

4: Everett PB, Senogles SE. D3 dopamine receptor signals to activation of phospholipase D through a complex with Rho. J Neurochem. 2010 Feb;112(4):963-71. doi: 10.1111/j.1471-4159.2009.06508.x. Epub 2009 Dec 18. PubMed PMID: 20021566.

5: Kitrey ND, Clément P, Bernabé J, Alexandre L, Giuliano F. Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-N,N-di-n-propylaminotetralin hydrobromide into the hypothalamic medial preoptic area induced ejaculation in anesthetized rats. Neuroscience. 2007 Nov 9;149(3):636-41. Epub 2007 Jul 20. PubMed PMID: 17916409.

6: Ito S, Mori T, Sawaguchi T. Differential effects of micro-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice. Behav Pharmacol. 2006 Dec;17(8):691-701. PubMed PMID: 17110795.

7: Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther. 2005 Jul;314(1):310-9. Epub 2005 Apr 15. PubMed PMID: 15833897; PubMed Central PMCID: PMC1201434.

8: Rogóz Z, Skuza G, Kłlodzińska A. Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats. Pol J Pharmacol. 2004 Sep-Oct;56(5):519-26. PubMed PMID: 15591639.

9: Cook CD, Beardsley PM. Modulation of the discriminative stimulus effects of mu opioid agonists in rats: II. Effects of dopamine D2/3 agonists. Behav Pharmacol. 2004 Feb;15(1):75-83. PubMed PMID: 15075629.

10: Rogóz Z, Skuza G, Kłodzińska A. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Pol J Pharmacol. 2003 May-Jun;55(3):449-54. PubMed PMID: 14506325.

11: Skuza G, Rogóz Z. A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist. Behav Pharmacol. 2002 Nov;13(7):537-43. PubMed PMID: 12409992.

12: Ottani A, Ferrari F, Giuliani D. Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):91-6. PubMed PMID: 11853125.

13: Levens N, Green TA, Akins CK, Bardo MT. Dopamine D(2)-like receptor binding in the brain of male Japanese quail (Coturnix japonica). Neurosci Lett. 2000 Dec 22;296(2-3):77-80. PubMed PMID: 11108985.

14: Dastur FN, McGregor IS, Brown RE. Dopaminergic modulation of rat pup ultrasonic vocalizations. Eur J Pharmacol. 1999 Oct 8;382(2):53-67. PubMed PMID: 10528139.

15: Geter-Douglass B, Katz JL, Alling K, Acri JB, Witkin JM. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists. J Pharmacol Exp Ther. 1997 Oct;283(1):7-15. PubMed PMID: 9336302.

16: Mallet PE, Beninger RJ. 7-OH-DPAT produces place conditioning in rats. Eur J Pharmacol. 1994 Aug 22;261(3):R5-6. PubMed PMID: 7813542.

Your view history

7-OH-DPAT Hydrobromide featured